An up-to-date overview of a range of topics, covering contemporary concerns and therapeutic challenges in clinical psychiatry, written by distinguished psychiatrists who are leaders in their fields. This volume will help to shape the clinical practice of psychiatry students and mental health professionals.
Contemporary Topics in Women’s Mental Health: Global Perspectives in a Changing Society considers both the mental health and psychiatric disorders of women in relation to global social change. The book addresses the current themes in psychiatric disorders among women: reproduction and mental health, service delivery and ethics, impact of violence, disasters and migration, women’s mental health promotion and social policy, and concludes each section with a commentary discussing important themes emerging from each chapter. Psychiatrists, sociologists and students of women’s studies will all benefit from this textbook. With a Foreword by Sir Michael Marmot, Professor of Epidemiology and Public Health, University College London; Chair, Commission on Social Determinants of Health
Drugs in Psychiatric Practice present a comprehensive examination of the drug treatment in psychiatry. It discusses certain ways in which drugs behaved. It addresses the advances in pharmacology and the basis of prescription. Some of the topics covered in the book are the classification of psychotropic drugs; basic principles of pharmacokinetics and drug metabolism; anti-schizophrenic drugs; evaluation of psychotropic drugs; unconventional chemotherapy; anti-parkinsonian and anti-dyskinetic drugs; introduction of amitriptyline; and tricyclic antidepressants. The role of tricyclic drugs in the treatment of enuresis and the drug treatment of organic brain syndrome are fully covered. An in-depth account of the monoamine oxidase inhibitors and amine precursors are provided. The tolerance and pharmacological dependence on alcohol are completely presented. A chapter is devoted to the factors involve in ethanol metabolism. Another section focuses on the unwanted effects of psychotropic drugs. The book can provide useful information to doctors, pharmacists, psychologists, students, and researchers.
Since the APA's last report on tardive dyskinesia in 1979, considerable research has been conducted on the prevalence, incidence, and risk factors associated with the development of late-occurring neuroleptic side effects. This book summarizes the progress made over the last decade in understanding the differential diagnosis and epidemiology of tardive dyskinesia, as well as risk factors, course, and treatment. The reader will benefit from the book's coverage of * indications for neuroleptic use* alternative maintenance strategies* factors to consider in making a differential diagnosis* frequently encountered problems in dealing with special populations such as children and mentally retarded people* clinical-legal issues related to tardive dyskinesia * clearly specified recommendations for prevention and management
. . . to the Clinician Although huge quantities of drugs are dispensed daily by psychiatrists, there appears to be insufficient concern about the short and long term effects of these exogenous agents on the recipients - our patients. Many clinicians have been trained at a time when knowledge of clinical psychopharmacology was super ficial at best, and recent trainees do not necessarily have access to newer, con stantly changing, relevant information. The busy clinician is frequently depen dent upon the limited knowledge dispensed by the drug company representatives and naturally shys away from many of the more esoteric contributions appearing in the literature. Because of the foregoing issues, the Executive of the Clarke Institute of Psychiatry of the University of Toronto, with the financial support of the Ministry of Health of the Government of Ontario, organized an inter national symposium on May 14-17, 1982, to bring together some of the acknowledged experts in clinical psychopharmacology. This book is, in part, a reflection of that symposium. The editors are aware that a contributed volume, however tightly edited, is not necessarily a textbook. Notwithstanding this, it was thought to be important to assemble expert opinion on current important issues, of immediate concern to the practicing clinician. With this in mind, the chapters have been organized around five themes. Schizophrenia, Affective disorders, and Anxiety, are clearly important since they are the major targets of drug use in psychiatry.
Mental health and HIV/AIDS are closely interlinked. Mental disorders, including substance-use disorders, are associated with increased risk of HIV infection and affect adherence to and efficacy of antiretroviral treatments. Conversely, HIV infection can increase risk for neuropsychiatric complications including stress, mood, and neurocognitive disorders. This book provides clinicians with a comprehensive evidenced-based and practical approach to the management of patients with HIV infection and co-morbid mental disorders. It provides up-to-date and clear overviews of current clinical issues, as well as the relevant basic science. Information and data from studies of different HIV groups (eg men who have sex with men) make the text relevant to a broad spectrum of clinicians, including those working with low socioeconomic status groups in high income countries and those working in the developing world. The book uses the popular format of the World Psychiatric Association’s Evidence and Experience series. Review chapters summarize the evidence on the epidemiology, pathogenesis and clinical aspects of mental disorders in HIV,and interventions (both psychotherapy and psychopharmacology including drug-drug interactions). These are complemented by commentaries addressing particular facets of each topic and providing insight gained from clinical experience. Psychiatrists, psychologists and all mental health staff working with HIV-infected patients will find this book of great benefit.